Skip to main content
Download PDF

APOE genotype and biological sex regulate astroglial interactions with amyloid plaques in Alzheimer’s disease mice

Journal of Neuroinflammation volume 19, Article number: 286 (2022) Cite this article

Abstract

The most significant genetic risk factor for developing late-onset Alzheimer’s disease (AD) is the ε4 allele of apolipoprotein E (APOE4). APOE genotype and biological sex are key modulators of microglial and astroglial function, which exert multiple effects on AD pathogenesis. Here, we show astroglial interactions with amyloid plaques in the EFAD transgenic mouse model of AD. Using confocal microscopy, we observed significantly lower levels of astrocytic plaque coverage and plaque compaction (beneficial effects of glial barrier formation) with APOE4 genotype and female sex. Conversely, neurite damage and astrocyte activation in the plaque environment were significantly higher in APOE4 carriers and female mice. Astrocyte coverage of plaques was highest in APOE3 males and poorest in APOE4 females. Collectively, our findings provide new insights into the roles of astroglia and highlight the importance of addressing independent and interactive effects of APOE genotype and biological sex in understanding processes contributing to AD pathogenesis.

Introduction

Alzheimer’s disease (AD) is an age-related neurodegenerative disease and the most common cause of dementia. A primary pathological hallmark of AD is the accumulation of β-amyloid protein (Aβ), which is implicated in driving neurodegenerative cascades [1], in the form of extracellular plaques. Another component of AD pathophysiology is activated glia. Both microglia and astrocytes exhibit activated phenotypes and are often co-localized with plaques [2]. While microglia are known to exhibit both positive and negative outcomes in AD, much less is known about the role of astrocytes, even though their presence near plaques is well-documented [3].

Astrocytes are the most numerous cell type in the brain and display extensive heterogeneity and phenotypic plasticity [4, 5]. Their role ranges from scar formation to energy provision and essential synapse maintenance [6]. These responses are altered and can be severely compromised when astrocytes adopt an activated phenotype [7, 8]. However, it is unclear whether reactive astrocytes closely associated with amyloid plaques play a protective and or harmful role in regulating AD. One way in which glia modulate AD pathogenesis is via interactions with amyloid plaques. For example, microglial processes form a barrier-like network around plaques that is associated with restricted outward expansion of Aβ plaque fibrils and protection against neuritic damage [9]. Whether astrocytes form similar protective barriers is not known.

Development of AD is significantly affected by several risk factors. The most significant genetic risk factor for AD is the ε4 allele of apolipoprotein E (APOE4), which increases risk up to 15-fold compared to the more prevalent ε3 allele (APOE3) [10]. ApoE is an abundant glycoprotein that is synthesized and secreted in the CNS mainly by astrocytes [11] and regulates several AD-related processes, including Aβ uptake and degradation [12, 13], that are mediated in part by astrocytes [11]. A complex interplay exists between sex and APOE. While female sex confers higher risk of developing AD, APOE4 interacts with sex to significantly impact AD pathways that involve neuroinflammation. Astrocytes and microglia support neuronal function and are key modulators of neuroinflammation. Our previous work has shown that microglia have protective interactions with plaques that are dependent on APOE genotype and sex [14]. Because astrocytes and microglia are intimately linked, we investigated the astrocyte interactions with amyloid plaques in relation to APOE status and biological sex.

Methods

Animals

The EFAD mice used in this study are hemizygous for 5xFAD transgenes and homozygous for targeted replacement of mouse APOE with human APOE3 (E3FAD) or APOE4 (E4FAD) [15]. Mice were euthanized at 6 months, an age characterized by significant AD-related neuropathology [16]. After mice were perfused with 4 °C PBS, the brains were extracted and fixed in 4% paraformaldehyde for 48 h. Four groups of mice were studied (n = 6 per group): male and female E3FAD, male and female E4FAD. This study was performed under an institutionally approved animal protocol and in accordance with the guidelines of the National Institutes of Health.

Histochemistry

Fixed brains were sectioned (40 μm) in the sagittal plane with at least three medial, equidistantly spaced sections per brain stained using modifications of previously described protocols [14]. Staining batches were balanced across groups. In brief, sections were permeabilized in Triton X-100 for 15 min, followed by incubation at 4 °C with primary antibodies (diluted in blocking buffer) against glial fibrillary acid protein (GFAP, DAKO, 1:500), lysosomal-associated membrane protein 1 (LAMP1) (DHSB, 1:250), and or Ab (MOAB-2, Sigma-Aldrich, 1:100). After subsequent washing, sections were incubated with Alexa fluorophore-conjugated secondary antibodies (Invitrogen; anti-rabbit, anti-mouse, anti-rat) diluted 1:500 in blocking buffer. To label amyloidogenic plaques, immunostained sections were incubated with 0.5% THK-265 (THK; Sigma-Aldrich) for 20 min, washed with PBS, then mounted with ProLong Gold Antifade medium (Vectashield).

Microscopy and image analyses

Image collection and analysis were performed as described [14] except as noted. In brief, a Zeiss-780 upright confocal microscope with ZEN imaging software (Zeiss) was used for image capture with researcher-blinded acquisition. Laser and detector settings were maintained across imaging sessions and high-resolution z-stack images were collected with optimal section depths (~ 0.35 µm). A 63× oil immersion objective (1.4 NA) was used to acquire regions of interest (ROI, 192.8 µm × 192.8 µm, 512 × 512 pixels, 16 bit) in the subiculum and cornu ammonis 1 (CA1) stratum radiatum fields of hippocampus, sampling areas with individual plaques. Analyses were performed using a custom ImageJ blinding plugin [17]. Images were de-noised and average projections were used for analysis.

Plaque coverage, size, and compaction were quantified from all plaques > 4 µm in diameter that were fully contained within the ROIs (≥ 3 per section, three sections per animal) and did not overlap with other plaques; 2–10 plaques were analyzed per animal. Plaque coverage was defined as the contact area between astrocyte processes and THK-265+ plaques (within 2 µm), calculated by summing arcs of plaque perimeters across three-dimensional stacks. Plaque area was manually determined in ImageJ and ranged from 10 to 108 µm2. Plaque circularity (a measure of compaction) was determined using the formula 4π × area/(perimeter)2.

Neuronal dystrophy was determined as a ratio, quantifying LAMP1 lysosomal staining density normalized to the corresponding THK-265+ plaque area. Analyses of individual astrocytes (3–41 cells/animal) included all non-overlapping GFAP-immunoreactive cells fully within the ROIs and within a 100 µm radius of THK-265+ plaques. Soma size was measured by manually identifying, outlining, and measuring GFAP-immunoreactive cell bodies using ImageJ. Astrocyte primary process number was manually determined as the number of processes emanating directly from GFAP-labeled somas as previously described [18].

Statistical analyses

Two-way analysis of variance, with APOE genotype and sex as independent variables was performed using Prism (GraphPad Software, Inc. version 9), followed by Tukey post-hoc test to account for multiple comparisons. Kolmogorov–Smirnov and Shapiro–Wilk tests were used to test sample normality distribution. Kruskal–Wallis test was used to compare differences between groups whose distributions did not pass normality testing. Data are presented as box (mean and 25th and 75th quartiles) and whisker (minimum and maximum values) plots or as means (+ SEM). For all statistical tests, p values less than 0.05 were considered significant.

Results

To investigate astrocyte–plaque interactions and determine the effects of APOE genotype and biological sex, we first examined astrocyte association with Ab plaques. GFAP-labeled cells were colocalized predominantly with Ab-immunolabeled deposits that were also positive for the amyloid stain THK-265 in a manner that was similar across APOE genotype and sex (Additional file 1: Fig. S1). Next, we measured the close associations (within 2 µm) of GFAP-labeled processes with THK-265-labeled amyloid. The local interactions of these processes with plaques, termed plaque coverage, is consistent with prior descriptions of microglia creating a barrier-like net around amyloid deposits [9, 19]. Importantly, APOE4 (F(1,76) = 30.2, p < 0.0001) and female sex (F(1,76) = 22.3, p < 0.0001) negatively affect the barrier-like interactions that astrocyte processes form around amyloid plaques, with a significant interaction between APOE and sex (F(1,76) = 15.8, p < 0.0002) (Fig. 1A, B). Specifically, E3FAD male mice have the highest degree of astrocyte–plaque coverage, which is significantly lower in E4FAD male mice (p < 0.0001) and female E3FAD (p < 0.0001) and E4FAD (p < 0.0001) mice (Fig. 1A, B). Astrocyte–plaque coverage is not strictly related to astrocyte abundance as GFAP immunoreactive burden is lowest in male E3FAD and highest in female E4FAD mice (Additional file 1: Fig. S2), which parallels the increasing abundance of plaque pathology in EFAD mice with APOE4 genotype and female sex [15, 20].

Fig. 1
figure 1

APOE4 and female sex reduce protective astrocyte interactions with amyloid plaques. A Representative confocal images of THK-265-positive amyloid plaques (cyan), GFAP-immunoreactive astrocytes (green), LAMP1-positive dystrophic neurites (magenta) and cell nuclei labeled with 4′,6-diamidino-2-phenylindole (dark blue) in male and female E3FAD and E4FAD mice. Scale bars = 10 μm. Amyloid plaques were quantified for B coverage with GFAP-immunoreactive astrocyte processes, C plaque circularity, D plaque area, and E LAMP1-positive dystrophic neurites (normalized to plaque area) in male (E3M) and female (E3F) E3FAD and male (E4M) and female (E4F) EFAD mice. Data are presented as box (mean and 25th and 75th quartiles) and whisker (minimum and maximum values) plots from n = 6/group of mice at age 6 months. *p < 0.05, **p < 0.01, ***p < 0.001

Full size image

The plaque barrier that microglia form is associated with increased plaque compaction and reduced levels of dystrophic neurites (DNs) [9]. Plaque size and circularity were measured to understand how astroglial coverage affects plaque structure. There were significant main effects of sex (F(1,72) = 18.7, p < 0.0001), APOE genotype (F(1,72) = 8.9, p = 0.004), and APOE × sex interaction (F(1,72) = 30.7, p < 0.0001) on plaque circularity with male E3FAD mice showing the highest values (Fig. 1C). Plaque area was significantly affected by sex (F(1,72) = 37.4, p < 0.0001), such that female mice, regardless of APOE genotype, had significantly larger plaques (Fig. 1D). Plaque size differences do not appear to explain observed relationships as we noted numerous examples of strong astrocyte–plaque coverage with relatively large plaques in male E3FAD mice and weak astrocyte–plaque coverage with relatively small plaques in female E4FAD mice (Additional file 1: Fig. S3). We subsequently addressed plaque-associated LAMP1 labeling, a lysosomal marker known to exhibit high expression in plaque-associated DNs [21,22,23,24]. LAMP1 was used to establish whether astroglial plaque coverage was associated with neurite dystrophy. LAMP1 staining was significantly affected by sex (Fig. 1D, F(1,72) = 7.4, p = 0.008) and APOE genotype (F(1,72) = 8.3, p = 0.005). The highest levels of LAMP1 were observed in female E4FAD mice compared to male E3FAD mice (Fig. 1E, p = 0.003).

Finally, the morphological phenotype of plaque-associated astrocytes was assessed to inform on activation state, which includes hypertrophy of astrocyte processes and increased soma size [18]. Significant main effects of both sex and APOE genotype on astrocyte soma area (sex: F(1,52) = 21.6, p < 0.0001, APOE: F(1,52) = 10.6, p = 0.002), and a significant main effect of sex on number of primary processes (sex: F(1,45) = 26.9, p < 0.0001) were observed. Astrocytes from male E3FAD mice showed significantly higher process number and significantly lower soma area than female E4FAD mice (Fig. 2A–C, process number p = 0.0003, soma p < 0.0001). These results indicate that astrocytes proximal to amyloid plaques exhibit evidence of activation.

Fig. 2
figure 2

APOE4 and female sex alter activation phenotype of near-plaque astrocytes. A Representative confocal images of THK-265-positive amyloid plaques (cyan) and individual GFAP-immunoreactive astrocytes (pseudo-colored orange–purple). Scale bars = 10 μm. Quantification of B astrocyte primary process number, and C astrocyte soma area in male (E3M) and female (E3F) E3FAD and male (E4M) and female (E4F) EFAD mice. Data are presented as box (mean and 25th and 75th quartiles) and whisker (minimum and maximum values) plots from n = 6/group of mice at age 6 months. *p < 0.05, **p < 0.01

Full size image

Discussion

Astrocytes are important regulators of AD pathogenesis and are known to interact directly with amyloid plaques [25, 26]. However, the functional consequences of astroglial interactions with plaques have not been fully elucidated. This study describes novel astrocyte interactions with amyloid plaques in the EFAD mouse model of AD. We report astrocyte plaque coverage that is positively associated with plaque compaction and negatively associated with neuritic damage. These observations suggest that like microglia, astrocyte plaque interactions may serve a beneficial role by limiting neuronal associations with plaques.

Prior work has implicated astrocytes as regulators of AD pathogenesis [27]. However, it is still unclear how astrogliosis regulates disease progression given that activated astrocytes adopt phenotypes associated with both positive and negative outcomes [28]. The observed association between astrocyte–plaque coverage and both increased plaque circularity and reduced dystrophic neurites suggests that it is a beneficial function impaired in the context of APOE4. In line with this perspective, Mathur and colleagues observed that astrocyte interactions with plaque subtypes in AD brain were related to reduced cognitive impairment, including the finding of decreased astrocyte interactions with compact plaques predicting lower cognitive ability in a manner that was deleteriously affected by APOE4 [29]. Conversely, since APOE4 is associated with more rapid and extensive plaque pathology in EFAD mice [15], astrocyte–plaque interactions may reflect in part differing abundance of plaque pathology in age-matched APOE3 versus APOE4 mice, an issue that has been considered but remains unresolved [30]. In this case, one would predict that the patterns of astroglial–plaque interactions and Ab pathology show strong parallels across sex and APOE genotype, a relationship that is not found in our data. More specifically, the observed patterns of plaque coverage, plaque circularity and plaque-associated DNs show a clear separation between APOE3 males and all other groups, which share similar outcomes (i.e., APOE3 males > APOE3 females, APOE4 males, APOE4 females). In contrast, Ab pathology in EFAD mice exhibits a different, graded pattern with APOE3 males < APOE3 females, APOE4 males < APOE4 females [20, 31]. The lack of concordance between astroglial–plaque interactions and measures of AD-related pathology suggest the possibility of inherent sex and APOE genotype effects. Indeed, there are numerous observations of sex × APOE interactions across multiple domains in the absence of significant Ab pathology in rodents and humans [32,33,34,35,36].

Our findings demonstrate that astrocyte coverage of plaques is significantly reduced by female sex. Specifically, we find that astrocytes in male E3FAD mice show greater astrocyte coverage, elevated plaque compaction, and lower levels of neurite injury; these effects are significantly diminished by female sex with both APOE3 and APOE4 genotypes. The mechanisms underlying observed sex differences in astrocyte actions remain to be elucidated. It is well-established that sex differences in AD are associated with both organizational effects of gonadal hormones during developmental periods [37, 38] and sex-specific abundance and age-related depletions of these hormones [39]. Astrocytes are known to participate in sexual differentiation of the brain and exhibit a range of sexual dimorphisms in function [40].

Our observations that astrocyte–plaque coverage is regulated by sex and APOE genotype parallels our prior observations with microglia [14]. More specifically, our findings indicated that microglia may protect neurons from amyloid by closely associating with amyloid plaques, but that APOE4 and female sex yielded poorer microglial coverage. Astrocytes interact with fibrillar plaques in a complementary manner to that of microglia. It remains to be clarified whether astrocytes, microglia or perhaps their interactions are most important to glial plaque coverage. Recent proteomic work implicates changes in both astroglial and microglial protein markers as among the earliest events in AD development [41].

There are some limitations to this study. First, we labeled astrocytes with GFAP, a marker of astrocyte activation that is widely used but can be restrictive in revealing very fine astrocyte processes and is not a ubiquitous marker for all astrocytes [42]. Second, our findings are derived from a transgenic mouse model of AD, all of which have limitations that may restrict translation to human AD [43]. Third, this initial report did not vary parameters that can influence APOE-modulated glial outcomes in AD mice, including age [30] and brain region [44]. In addition, the analytic demands limited the total numbers of plaques and astrocytes studied, reinforcing the need for further study of the observed relationships.

In summary, these data provide the first clear evidence that astrocytes interact with amyloid plaques in a manner that is associated with both smaller plaque size and reduced plaque-associated neuritic damage. These astrocytic interactions are regulated by biological sex and APOE genotype. Collectively, these findings provide new insight into the role of glia as contributors to the relationships among sex, APOE, and AD.

Availability of data and materials

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

AD:

Alzheimer’s disease

Aβ:

β-Amyloid

APOE :

Apolipoprotein E

CA1:

Cornu ammonis 1

CNS:

Central nervous system

DNs:

Dystrophic neurites

GFAP:

Glial Fibrillary Acid Protein

LAMP1:

Lysosomal-associated membrane protein 1

ROI:

Region of interest

References

  1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8:595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sidoryk-Wegrzynowicz M, Wegrzynowicz M, Lee E, Bowman AB, Aschner M. Role of astrocytes in brain function and disease. Toxicol Pathol. 2011;39:115–23.

    Article  PubMed  Google Scholar 

  3. Nagele RG, D’Andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 2003;971:197–209.

    Article  CAS  PubMed  Google Scholar 

  4. Khakh BS, Deneen B. The emerging nature of astrocyte diversity. Annu Rev Neurosci. 2019;42:187–207.

    Article  CAS  PubMed  Google Scholar 

  5. Matias I, Morgado J, Gomes FCA. Astrocyte heterogeneity: impact to brain aging and disease. Front Aging Neurosci. 2019;11:59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Kastanenka KV, Calvo-Rodriguez M, Hou SS, Zhou H, Takeda S, Arbel-Ornath M, Lariviere A, Lee YF, Kim A, Hawkes JM, et al. Frequency-dependent exacerbation of Alzheimer’s disease neuropathophysiology. Sci Rep. 2019;9:8964.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Escartin C, Galea E, Lakatos A, O’Callaghan JP, Petzold GC, Serrano-Pozo A, Steinhäuser C, Volterra A, Carmignoto G, Agarwal A, et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat Neurosci. 2021;24:312–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, Münch AE, Chung WS, Peterson TC, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176.

    Article  CAS  PubMed  Google Scholar 

  10. Lumsden AL, Mulugeta A, Zhou A, Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK Biobank. EBioMedicine. 2020;59: 102954.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719–26.

    Article  CAS  PubMed  Google Scholar 

  12. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer’s disease: accidental encounters or partners? Neuron. 2014;81:740–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Stephen TL, Cacciottolo M, Balu D, Morgan TE, LaDu MJ, Finch CE, Pike CJ. APOE genotype and sex affect microglial interactions with plaques in Alzheimer’s disease mice. Acta Neuropathol Commun. 2019;7:82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N, Valencia-Olvera AC, LaDu MJ. EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer’s disease. J Lipid Res. 2017;58(9):1733–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Stephen TL, Higgs NF, Sheehan DF, Al Awabdh S, López-Doménech G, Arancibia-Carcamo IL, Kittler JT. Miro1 regulates activity-driven positioning of mitochondria within astrocytic processes apposed to synapses to regulate intracellular calcium signaling. J Neurosci. 2015;35:15996–6011.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Sun D, Jakobs TC. Structural remodeling of astrocytes in the injured CNS. Neuroscientist. 2012;18:567–88.

    Article  PubMed  Google Scholar 

  19. Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90:724–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cacciottolo M, Christensen A, Moser A, Liu J, Pike CJ, Smith C, LaDu MJ, Sullivan PM, Morgan TE, Dolzhenko E, et al. The APOE4 allele shows opposite sex bias in microbleeds and Alzheimer’s disease of humans and mice. Neurobiol Aging. 2016;37:47–57.

    Article  CAS  PubMed  Google Scholar 

  21. Condello C, Schain A, Grutzendler J. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci Rep. 2011;1:19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sharoar MG, Palko S, Ge Y, Saido TC, Yan R. Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains. Mol Neurodegener. 2021;16:45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer’s disease amyloid plaques. Proc Natl Acad Sci USA. 2015;112:E3699-3708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sadleir KR, Popovic J, Khatri A, Vassar R. Oral nimodipine treatment has no effect on amyloid pathology or neuritic dystrophy in the 5XFAD mouse model of amyloidosis. PLoS ONE. 2022;17: e0263332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173–82.

    Article  CAS  PubMed  Google Scholar 

  26. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer’s disease. Neurotherapeutics. 2010;7:399–412.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Arranz AM, De Strooper B. The role of astroglia in Alzheimer’s disease: pathophysiology and clinical implications. Lancet Neurol. 2019;18:406–14.

    Article  CAS  PubMed  Google Scholar 

  28. Perez-Nievas BG, Serrano-Pozo A. Deciphering the astrocyte reaction in Alzheimer’s disease. Front Aging Neurosci. 2018;10:114.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Mathur R, Ince PG, Minett T, Garwood CJ, Shaw PJ, Matthews FE, Brayne C, Simpson JE, Wharton SB. A reduced astrocyte response to β-amyloid plaques in the ageing brain associates with cognitive impairment. PLoS ONE. 2015;10: e0118463.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fitz NF, Wolfe CM, Playso BE, Biedrzycki RJ, Lu Y, Nam KN, Lefterov I, Koldamova R. Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol Neurodegener. 2020;15:41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Balu D, Karstens AJ, Loukenas E, Maldonado Weng J, York JM, Valencia-Olvera AC, LaDu MJ. The role of APOE in transgenic mouse models of AD. Neurosci Lett. 2019;707: 134285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhao N, Ren Y, Yamazaki Y, Qiao W, Li F, Felton LM, Mahmoudiandehkordi S, Kueider-Paisley A, Sonoustoun B, Arnold M, et al. Alzheimer’s risk factors age, APOE genotype, and sex drive distinct molecular pathways. Neuron. 2020;106:727-742.e726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Takeuchi H, Tomita H, Browne R, Taki Y, Kikuchi Y, Ono C, Yu Z, Nouchi R, Yokoyama R, Kotozaki Y, et al. Sex-dependent effects of the APOE ɛ4 allele on behavioral traits and white matter structures in young adults. Cereb Cortex. 2021;31:672–80.

    Article  PubMed  Google Scholar 

  34. Li T, Pappas C, Le ST, Wang Q, Klinedinst BS, Larsen BA, Pollpeter A, Lee LY, Lutz MW, Gottschalk WK, et al. APOE, TOMM40, and sex interactions on neural network connectivity. Neurobiol Aging. 2022;109:158–65.

    Article  CAS  PubMed  Google Scholar 

  35. Sampedro F, Vilaplana E, de Leon MJ, Alcolea D, Pegueroles J, Montal V, Carmona-Iragui M, Sala I, Sánchez-Saudinos MB, Antón-Aguirre S, et al. APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget. 2015;6:26663–74.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Foley KE, Diemler CA, Hewes AA, Garceau DT, Sasner M, Howell GR. APOE ε4 and exercise interact in a sex-specific manner to modulate dementia risk factors. Alzheimers Dement. 2022;8: e12308.

    Google Scholar 

  37. Luo J, Beam C, Karlsson I, Pike CJ, Reynolds CA, Gatz M. Dementia risk in women higher in same-sex than opposite-sex twins. Alzheimers Dement. 2020;12(1): e12049.

    Google Scholar 

  38. Jiang J, Young K, Pike CJ. Second to fourth digit ratio (2D:4D) is associated with dementia in women. Early Hum Dev. 2020;149: 105152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Pike CJ. Sex and the development of Alzheimer’s disease. J Neurosci Res. 2017;95:671–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Mong JA, Kurzweil RL, Davis AM, Rocca MS, McCarthy MM. Evidence for sexual differentiation of glia in rat brain. Horm Behav. 1996;30:553–62.

    Article  CAS  PubMed  Google Scholar 

  41. Johnson ECB, Dammer EB, Duong DM, Ping L, Zhou M, Yin L, Higginbotham LA, Guajardo A, White B, Troncoso JC, et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med. 2020;26:769–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Preston AN, Cervasio DA, Laughlin ST. Visualizing the brain’s astrocytes. Methods Enzymol. 2019;622:129–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Martini AC, Forner S, Trujillo-Estrada L, Baglietto-Vargas D, LaFerla FM. Past to future: what animal models have taught us about Alzheimer’s disease. J Alzheimers Dis. 2018;64:S365-s378.

    Article  PubMed  Google Scholar 

  44. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. J Neuroinflammation. 2014;11:111.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

EFAD mice were provided through a Material Transfer Agreement with Dr. Mary Jo LaDu (University of Illinois Chicago). The authors thank Ms. Wenjie Qian and Dr. Amy Christensen for animal work, and Dr. Deebika Balu (University of Illinois Chicago) for generously providing additional tissue samples.

Funding

This study was supported by grants from the Cure Alzheimer’s Fund (CJP and CE Finch) and National Institute for Aging (RF1AG058068, CJP, M Gatz, MJ LaDu; 1T32AG052374, KJA Davies). The funding agencies were not involved in the study design, in the collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Authors and Affiliations

  1. Leonard Davis School of Gerontology, University of Southern California, 3715 McClintock Avenue, Los Angeles, CA, 90089-0191, USA

    T. L. Stephen, B. Breningstall, S. Suresh, C. J. McGill & C. J. Pike

Authors
  1. T. L. Stephen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Breningstall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Suresh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. J. McGill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. J. Pike
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TS contributed to the conceptualization and experimental design of the study, performed staining, imaging, and statistical analyses for Figs. 1, 2 and Additional file 1: Fig. S3, and co-wrote and edited the manuscript. BB contributed to experimental design, tissue staining, data collection, and analyses of Additional file 1: Figs. S1, S2. SS was involved with tissue preparation, sectioning, and staining. CJM contributed to experimental design and statistical analyses of Additional file 1: Figs. S1, S2 and edited the manuscript. CJP contributed to the conceptualization and experimental design of the study, co-wrote and edited the manuscript, and provided the necessary resources. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to C. J. Pike.

Ethics declarations

Ethics approval and consent to participate

This study was performed under an institutionally approved animal protocol and in accordance with the guidelines of the National Institutes of Health.

Consent for publication

Not applicable.

Competing interests

CJP is a consultant for Holy Stone Healthcare Co., LTD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Astrocytes colocalize with amyloid plaques across APOE genotypes and sex. Figure S2. Astrocyte immunoreactive load varies across APOE genotypes and sex. Figure S3. Astrocyte immunoreactive load varies across APOE genotypes and sex.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stephen, T.L., Breningstall, B., Suresh, S. et al. APOE genotype and biological sex regulate astroglial interactions with amyloid plaques in Alzheimer’s disease mice. J Neuroinflammation 19, 286 (2022). https://doi.org/10.1186/s12974-022-02650-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12974-022-02650-4

Keywords

Journal of Neuroinflammation

ISSN: 1742-2094